Kornimate/medical-research-clean huggingface dataset:
application of diffusion tensor imaging and tractography in epilepsy surgery

Conditions: Temporal Lobe Epilepsy

Summary: using synaptive medical's brightmatter™ products to better visualize and plan epilepsy surgeries by considering white matter tracts, and considering whether the technology results in improved clinical outcomes.

a common goal of focal brain resection is the removal of a lesion while preserving healthy eloquent tissues of the brain. one such eloquent area that is commonly aimed to be preserved are the white matter nerve fiber tracts which is critical of brain communication and function. this study aims to investigate whether the use of synaptive medical's brightmattertm technology can help neurosurgeons to better visualize and plan surgeries by considering the white matter tracts, and whether it results in improved clinical outcomes. this study will investigate the preservation of the optic radiations in anterior temporal lobectomy epilepsy surgeries.

Eligibility criteria:
inclusion criteria: * patients diagnosed with temporal lobe epilepsy between 18 and 65 years of age. * patients whose seizures are disabling and/or are not controlled by any form of epileptic medication. * patients whose clinical pre-surgical investigations indicates the need for anterior temporal lobe resection (atlr). exclusion criteria: * prior resective epilepsy surgery. * past or planned non resective epilepsy surgery (such as a corpus callosotomy and vagal nerve stimulator placement). * contraindication to mri, and/or whom are (or suspect to) being pregnant. * complicated medical problems such as cancer or heart disease.
the association between high risk pregnancy and sleep-disordered breathing

Conditions: Preeclampsia; Gestational Diabetes; Premature Labor

Summary: the aim of the present study is to establish, using polysomnographic criteria and prospective nature, whether sleep apnea in pregnancy is more prevalent in women with high risk pregnancies including preeclampsia, gestational diabetes, and pre-mature contractions, and to determine the effect of sleep disordered breathing in pregnancy on fetal outcome. the investigators' hypothesis is that sleep-disordered breathing is more prevalent in women with high risk pregnancy compared to those with uncomplicated pregnancy.

over the last decade, the association between sleep disordered breathing and pregnancy outcome has been described primarily in case reports. although recently, larger studies describing adverse pregnancy outcomes in women with sleep disordered breathing has begun to emerge, these studies often lack polysomnographic data and the true prevalence of sleep disordered breathing in pregnancy is not known. we intend to recruit 100 women at the third trimester of pregnancy, who are admitted to the high risk pregnancy unit with pre-eclampsia, gestational diabetes, or premature labor. an additional group of 50 women at the third trimester of an uncomplicated pregnancy will be recruited. all women will fill questionnaires regarding the pregnancy and their sleep and will undergo an overnight sleep study. women will then be followed until birth. pregnancy complication, birth and perinatal course will be recorded. cord blood will be collected from all infants and evaluated for inflammatory cytokines, reactive oxygen species and growth factors. infants will then be followed for 1 year. their growth, development and intercurrent illnesses will be recorded.

Eligibility criteria:
inclusion criteria: * age 19 - 39 years * over 26 weeks of gestation * one of the following: 1. pre-eclampsia defined as systolic blood pressure \> 140 or diastolic blood pressure \> 90 and associated proteinuria \> 300 mg / 24 h urine collection. 2. gestational diabetes requiring insulin treatment 3. premature contractions with associated cervical dilation or effacement 4. uncomplicated pregnancy exclusion criteria: * chronic maternal disease * alcohol consumption during pregnancy * illicit drug abuse at any time in life * fetal abnormalities on obstetric ultrasound

Keywords: sleep apnea high risk pregnancy fetal outcome cord blood
evaluation of endoscopic treatment effect based on hvpg

Conditions: Esophageal and Gastric Varices

Summary: this study aims to evaluate the endoscopic treatment effect and related influencing factors of patients with esophageal and gastric varices based on hvpg. by enrolling and collecting patients with esophageal and gastric varices at different stages of liver cirrhosis, the changes in portal pressure before and during endoscopic treatment were detected. the endoscopic treatment effect of different patients was evaluated by combining the changes in hvpg and the condition of varicose veins, the effects of different endoscopic treatment methods on hvpg were analyzed, and the correlation between hvpg changes and endoscopic efficacy was explored.


Eligibility criteria:
inclusion criteria: 1. age range: 18-80 years old; 2. patients with confirmed cirrhosis through clinical, imaging or pathological evidence, with causes including viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, etc.; 3. patients with esophageal and gastric varices confirmed by endoscopic examination and varicose vein bleeding in the past; 4. endoscopic treatment (such as band ligation, sclerotherapy or colloid injection) is an appropriate secondary prevention method; exclusion criteria: * (1) combined with hepatocellular carcinoma or other malignant tumors; (2) autoimmune cirrhosis, schistosomal cirrhosis, hepatic venous occlusion, etc.; (3) combined with other diseases that affect portal hypertension, such as portal vein thrombosis; (4) recently (within 6 months) received other treatments, such as tips, liver transplantation, or other treatment measures that may affect the study; (5) accompanied by severe cardiopulmonary diseases (such as severe heart failure, copd, etc.);
lateral advancement flap versus classic limberg flap in the treatment of noncomplicated pilonidal sinus

Conditions: Pilonidal Sinus

Summary: background the flaps closure including natal cleft obliteration and eccentric closure are becoming more popular due to their lower rate of recurrence including both the lateral advancement adipo-fascio-cutaneous flap and the classic limberg flap. objective this study was aim to compare the results of the surgery for non-complicated pilonidal sinus with the lateral advancement adipo-fascio-cutaneous flap versus the classic limberg flap. patients and methods this study was a prospective randomized controlled, and was conducted on patients with non-complicated pilonidal sinus attending zagazig university hospitals, egypt during the period from february 2017 to august 2019. patients were randomly assigned to undergo either lateral advancement flap or classic limberg flap groups. the follow-up period ranged from 12 to 36 months. patient satisfaction, complications and recurrence rates were analyzed and compared.

hodges was the first to use the term "pilonidal" (which was derived from the latin pilus=hair and nidus=nest) in 1988. the pilonidal disease is usually predisposed by the presence of a deep natal cleft containing a lot of hairs within it, which is also supplies a good environment for maceration, sweating, hairs penetration, and bacterial contamination . a lot of surgical treatment techniques are described for pilonidal sinus disease as simple excision and packing, excision with primary midline closure, marsupialization and eccentric closure by different types of flaps. though no surgical technique has been widely accepted, but the flaps closure including natal cleft obliteration and eccentric closure are becoming more popular due to their lower rate of recurrence. although the off-midline approach seems optimal for closure, the standard off-midline surgery has not yet been concluded. according to our best knowledge, no randomized study has yet compared the lateral advancement adipo-fascio-cutaneous flap and the classic limberg flap. therefore, the aim of the present study was to compare in a randomized controlled trial the short-term results of the surgical treatment of non-complicated pilonidal sinus with the lateral advancement adipo-fascio-cutaneous flap versus the classic limberg flap.

Eligibility criteria:
inclusion criteria: * patients with non-complicated pilonidal sinus * whose ages ranged from 18 to 60years exclusion criteria: * elderly patients with comorbid diseases * scars from a previous pilonidal surgery or recurrent cases * abscess presentations * diabetes mellitus, immunodeficiency, or other co-morbidity * american society of anesthesiologists physical status classification grade iii-iv * age \ 60 years
photoaging reversing after picosecond laser with dla assessed by cellular resolution oct in asian patient with melasma

Conditions: Melasma

Summary: background melasma is a commonly acquired hypermelanosis that affects facial sun exposed areas, most commonly in asians and other darker skin type females. recent evidence has demonstrated melasma to be a photoaging disorder. the histological findings of melasma are similar to photoaging and include solar elastosis, increased mast cells and sebaceous glands, as well as increased vascularization. pendulous active melanocytes with weakened basal membranes, and changes in nuclear morphology and chromatin texture of adjacent basal keratinocytes also seemed to be a characteristic feature of melasma. objectives: to compare the difference of photoaging features of melasma skin and normal skin by optical coherence tomography (apollovue® s100 image system, a 510(k) class ii medical device) and reversal of photoaing features by 755nm picosecond alexandrite laser with diffractive lens. methodology: we enroll 20 adults with facial melasma. the patients received 755nm picosecond alexandrite laser with diffractive lens array over whole face at w0, w4, and w8. evaluation with visia, optical coherence tomography, cutometer mpa580 at w4, w8, w12. all the patients will be instructed with use of moisturizer, gentle cleaning, and sunscreen use. anticipated results and applications: this study expects to 1. understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with optical coherence tomography and other noninvasive methods. 2. set evidence based guidance for melasma treatment and set the protocol or clinical path.


Eligibility criteria:
inclusion criteria: * willing to sign a written inform consent form * adults over the age of 20. * patients with melasma on their faces. exclusion criteria: * have received any cosmetic treatments, e.g. laser, pulsed light, and chemical peels within six months before participating the trial. * have taken oral contraceptives or received hormone therapy within one year before participating the trial. * has other pigmented diseases or inflammatory diseases on face. * are pregnant or breastfeeding. * has conditions with poor wound healing, keloids or photosensitivity.

Keywords: basement membrane diffractive lens array melasma optical coherence tomography 755nm picosecond alexandrite laser photoaging vascularization visia®
the effect of exenatide on fasting bile acids

Conditions: Type 2 Diabetes Mellitus in Obese

Summary: newly diagnosed t2dm participants without hypoglycemic drugs intake were retrospective analyzed. plasma total bile acids in fasting state (ftbas) and other parameters were compared before and after exenatide treatment and correlation analysis between changes of ftbas and glycemic parameters.

newly diagnosed t2dm participants without hypoglycemic drugs intake were retrospective analyzed. plasma total bile acids in fasting state (ftbas) and other parameters were tested at baseline. then exenatide were applied to the t2dm participants for 12 weeks. ftbas and glycemic parameters were measured again after exenatide treatment, and correlation analysis between changes of ftbas and glycemic parameters were conducted to investigate the role of bas in the glycemic control effect of exenatide.

Eligibility criteria:
inclusion criteria: * newly diagnosed t2dm patients exclusion criteria: * history of hepatobiliary or pancreatic diseases * history of anti-diabetic drugs intake * change of anti-dyslipidemia therapy regimen * estimated glomerular filtration rate less than 60 ml/min/1.73 m\^2 * pregnancy
red blood cells from umbilical cord for transfusion of preterm infants

Conditions: Infant, Extremely Premature; Erythrocyte Transfusion; Umbilical Cord Issue

Summary: this study has been designed to demonstrate that red blood cell from umbilical cord blood (ucb-rbc) is a safe and available product for extremely preterm infants (epi) transfusion and that transfusion of ucb-rbc is non-less effective than rbc from adult donor for the treatment of anemia of prematurity in this group of patients.

prematurity is an important maternal and child health problem due to its incidence and associated complications. anaemia is a frequent problem in extremely preterm infants (epi) whose treatment often requires red blood cell (rbc) transfusion. this product is currently obtained from adult blood (ab) donor. the incidence of some prematurity complications have been demonstrated to increase with ab-rbc tranfusions mainly because of the higher oxygen tissue release, such as retinopathy of prematurity (rop), bronchopulmonary dysplasia (bpd), and necrotizing enterocolitis (nec). in addition, ab-rbc could contain small amounts of heavy metals that could be toxic for epi. rbc from umbilical cord blood (ucb-rbc) might be a better alternative as it does not change the hemoglobin profile and consequently might decrease the oxygen toxicity. several studies have evaluated the safety of ucb-rbc transfusions in preterm infants without finding a higher risk of complications compared with ab-rbc transfusions. a pilot study has been designed to evaluate the safety of ucb-rbc for transfusion in epi and to determine the feasibility and efficacy of ucb-rbc for transfusion in this group of patients.

Eligibility criteria:
inclusion criteria: * signed informed consent from parents or legal guardians * preterm infants born earlier than 28 weeks of gestational age. * admission to the neonatal intensive care unit of the participating hospital (hospital clínic of barcelona) exclusion criteria: * previous transfusion * isoimmunization * hydrops fetalis * major congenital malformations * congenital infections * hemoglobinopathies * extreme urgency of blood availability (hypovolemic shock, disseminated intravascular coagulopathy...) * be part of another clinical trial that may interfere with the results

Keywords: anaemia of prematurity extremely preterm infants umbilical cord blood blood bank fetal hemoglobin
dose escalation study of zg006 in participants with advanced small cell lung cancer or neuroendocrine carcinoma, followed by dose expansion study in participants with advanced small cell lung cancer

Conditions: Small Cell Lung Cancer; Neuroendocrine Cancer

Summary: this is a multicenter, open-label phase i/ii study, divided into 2 parts: part 1 involves a dose-escalation study of zg006 in which the safety and tolerability of zg006 in patients with advanced small cell lung cancer or neuroendocrine carcinoma are explored. upon completion of part 1, investigators and the sponsor will discuss and determine two recommended phase ii doses (rp2d) based on safety, preliminary efficacy, and pharmacokinetic (pk) results for use in part 2. part 2 is a phase ii dose-expansion study of zg006, aiming to investigate the efficacy and safety of zg006 in patients with advanced small cell lung cancer.


Eligibility criteria:
inclusion criteria: * fully understand the study and voluntarily sign the informed consent form; * male or female 18\~75 years of age; * eastern cooperative oncology group(ecog) performance status of 0 or 1; * life expectancy ≥ 3 months; exclusion criteria: * participants were deemed unsuitable for participating in the study by the investigator for any reason.
to compare the efficacy and safety of tripterygium wilfordii (tw) versus valsartan in the membranous nephropathy (mn)

Conditions: Membranous Nephropathy

Summary: the purpose of this study is to assess the efficacy of tw compared to valsartan in treatment of heavy proteinuria of membranous nephropathy.

membranous nephropathy with heavy proteinuria have high risks of progressing to crf. tripterygium (tw) is a chinese traditional patent drugs, it can reduce proteinuria of chronic glomerular nephritis,such as iga nephropathy. so, we designed this randomized, prospective clinical trial to assess the efficacy and safety of tw versus valsartan in the treatment of heavy proteinuria of mn.

Eligibility criteria:
inclusion criteria: * biopsy-proven idiopathic membranous nephropathy * nephrotic syndrome with proteinuria (\> 4 g/day) and serum albumin \< 30 g/dl * age over 18 with informed consent exclusion criteria: * patient with abnormal liver function tests * prior therapy with sirolimus, csa, mmf, tacrolimus or azathioprin, chlorambucil, levamisole, methotrexate, or nitrogen mustard in the last 90 days, * active/serious infection, * patient with hepatitis b surface antigen or who is hepatitis c antibody positive

Keywords: tw valsartan treatment membranous nephropathy proteinuria
efficacy and tolerability of the use of varicell compared with daflon

Conditions: Chronic Venous Insufficiency; Hemorrhoids

Summary: the purpose of this study is to evaluate the efficacy and tolerability of varicell compared to daflon, in reducing the symptoms caused by chronic venous insufficiency and hemorrhoidal syndrome.

to evaluate the efficacy of varicell compared with daflon in the symptomatic treatment of chronic venous insufficiency and hemorrhoidal syndrome. to evaluate the tolerability of the use of varicell compared with daflon in the symptomatic treatment of chronic venous insufficiency and hemorrhoidal syndrome.

Eligibility criteria:
inclusion criteria: * for both groups * patients who consent to participate in the study by signing the instrument of consent. * patients of all ethnic groups, of both sexes and aged at least 18 years old and maximum 65 years old; * being for seven days without any medication or treatment related to the venous system. * patients able to make proper use of medication; for group v - chronic venous insufficiency. * presence of at least two symptoms (pain, heaviness and discomfort) in the lower limbs with scores greater than 3 measured by visual analogue scale; * clinical diagnosis of varicose veins rating of 0 to 3 by ceap; in group h - hemorrhoidal syndrome. * presence of at least two symptoms (pain in the anorectal evacuation to walk and / or at rest, feeling of anal discomfort (burning, itching, irritation) to evacuate to walk and / or at rest, bloating in the anorectal region, the presence and intensity of bleeding in the anorectal region, the presence and intensity of mucus in the anorectal region) with a score equal to or greater than 3 measured by visual analogue scale; * clinical diagnosis of hemorrhoids grade 1 and grade 2. exclusion criteria: pregnant or lactating; * patients aged less than 18 years old or older than 65 years old; * patients with a history of hypersensitivity to any component of the formula; * use of medications phlebotonics in the last 7 days; * previous venous surgery; * patients with renal and liver failure. * patients with gastritis or gastric ulcer; * patients with acute inflammatory diseases of the bowel, intestinal obstruction, appendicitis; * patients with ileus, stenosis, atony, undiagnosed abdominal symptoms, colonopathy inflammatory abdominal pain of unknown cause dehydration and loss of water and electrolytes and constipation; * patients with blood coagulation disorders; * any condition which in the opinion of the physician investigator is significant and can make the patient unsuitable for study or that might put you under additional risk.

Keywords: chronic venous insufficiency hemorrhoidal syndrome varicell
two doses of dexmedetomidine as adjuvent to bupivacaine in tap block

Conditions: Post Operative Pain

Summary: the aim of this study to determine the optimal dose of dexmedetomidine as an adjuvant to bupivacaine in u.s guided tap block for preemptive analgesia in patients undergoing lower abdominal cancer surgeries.

the transversus abdominis plane (tap) involves innervations of the anterolateral abdominal wall derived from t6-l1. the block can be given either by anatomical landmark technique or by using an ultrasound probe. the local anesthetic is deposited in a plane between internal oblique and transversus abdominis muscle. it provides adequate postoperative analgesia following various abdominal surgeries.dexmedetomidine is an alpha-2 agonist that has been approved as a venous sedative and an adjuvant for pain relief .in previous studies, the addition of dexmedetomidine to bupivacaine in the tap block has prolonged the effect of this block . so far, the optimal dose of dexmedetomidine for the tap block has not been determined.

Eligibility criteria:
inclusion criteria: * age from 18 to 65 years old * lower abdominal cancer surgery exclusion criteria: * patient refusal * the local anesthetic allergy * coagulopathy * local infection at the procedure site * psychic patients * patient on chronic opioid use

Keywords: tap block dexmedetomidine